News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Piper Sandler has reiterated its Buy rating for Lexicon Pharmaceuticals (LXRX.US) and maintained its price target of $6. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Wall Street Zen downgraded Lexicon Pharmaceuticals (NASDAQ:LXRX) to a "Sell" rating from "Hold," despite broader analyst consensus remaining "Hold" with an average price target of $4.55. The downgrade follows Lexicon missing Q2 earnings estimates, reporting a $0.06 loss per share and significantly lower revenue …
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a Q2 adjusted loss of $0.06 per share, missing analyst estimates by $0.01. Revenue significantly declined to $0.69 million from $28.9 million year-over-year, largely due to a prior-year licensing payment. Despite the financial miss, the company completed enrollment for its …
Lexicon Pharmaceuticals, Inc.'s average stock price target has been raised from $3.77 to $3.86 by 5 analysts, with forecasts ranging from $2 to $6 per share. This updated target suggests a potential upside of approximately 57% based on the August 5 closing price. The …
Lexicon Pharmaceuticals reported its second-quarter 2026 financial results, which included total revenues of $15.5 million and a net loss of $28.3 million. The company also provided updates on its clinical development programs, notably the successful completion of the Phase 2 RELIEF-DIA study for LX9200 …
FMR LLC filed an amended Schedule 13G, disclosing a beneficial ownership of 11.7% in Lexicon Pharmaceuticals, Inc. common stock, totaling 51,782,044.66 shares. Abigail P. Johnson also holds sole dispositive power over the same amount. Notably, Fidelity Growth Company Commingled Pool accounts for 5.6% of …
Lexicon Pharmaceuticals, Inc. (LXRX) reported Q2 revenue of $692,000, significantly missing the FactSet estimate of $4.0 million. The biopharmaceutical company also announced its Q2 2026 earnings call for August 6, 2026, and earnings results for the second quarter and six months ended June 30, …
Lexicon Pharmaceuticals (LXRX) reported a Q2 loss of $0.07 per share, which was worse than FactSet's estimated loss of $0.05 per share. The company also announced Q2 revenue of $692,000, falling short of FactSet's estimate of $4.0 million. Lexicon Pharmaceuticals is focused on the …
Lexicon Pharmaceuticals reported a significant net loss of $31.8 million in Q2 2026, compared to a net income of $3.3 million in the prior-year quarter, primarily due to lower revenues from the absence of substantial licensing income and increased operating expenses. Despite the financial …
Lexicon Pharmaceuticals, Inc. (LXRX) closed at $2.3600, down 3.67%, with after-hours trading showing a further slight decrease. The company, focused on biopharmaceutical products, reported Q2 2026 earnings and has several drugs in development including sotagliflozin (INPEFA, ZYNQUISTA) and new candidates for obesity and neuropathic …
Lexicon Pharmaceuticals Inc is projected to report a loss of 5 cents per share, according to an earnings preview. This information is sourced from Reuters and is available on TradingView.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before market open. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss the results and provide a business update. …
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before market open. Management will host a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the …
This article provides a valuation analysis for Lexicon Pharmaceuticals Inc (LXRX), highlighting its current valuation score and P/E ratio. The company's valuation score is 8.54, ranking it 114 out of 384 in the Biotechnology & Medical Research industry, with a P/E ratio of -32.49. …
Lexicon Pharmaceuticals Inc. (LXRX) shows relatively healthy fundamentals and high growth potential, with its valuation considered fairly priced within the Biotechnology & Medical Research industry. The company is actively developing several drug candidates, including pilavapadin for neuropathic pain and LX9851 for obesity, and is …
This article provides a technical analysis of Lexicon Pharmaceuticals Inc (LXRX), detailing its price momentum, support and resistance levels, and indicator and moving average signals. Currently, LXRX has a price momentum score of 4.72, suggesting it's suitable for range-bound swing trading between resistance at …
Lexicon Pharmaceuticals (LXRX) recently completed patient randomization for its Phase 3 SONATA HCM trial, with results expected in early 2027. The company's stock shows strong momentum, having returned 105.26% year-to-date. Despite being considered undervalued with a fair value of $3.77 against a current price …
H.C. Wainwright has reiterated its Buy rating for Lexicon Pharmaceuticals (LXRX.US) and maintained its target price at $6. This indicates the firm's continued confidence in the company's stock performance and future prospects.
Lexicon Pharmaceuticals announced the completion of patient randomization for its pivotal Phase 3 SONATA-HCM trial of sotagliflozin, an oral inhibitor of SGLT1 and SGLT2, exceeding its enrollment target of 500 patients across 20 countries. The study includes both non-obstructive and obstructive hypertrophic cardiomyopathy patients, …
Lexicon Pharmaceuticals Inc (LXRX) has an institutional shareholding score of 5.00, placing it 132nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 67.79%, a slight decrease from the previous quarter. Steven Cohen is the largest institutional shareholder, …
Lexicon Pharmaceuticals announced the completion of enrollment for its pivotal Phase 3 SONATA-HCM clinical trial, evaluating sotagliflozin in patients with symptomatic non-obstructive and obstructive hypertrophic cardiomyopathy (HCM). The study enrolled over 500 patients across more than 130 sites in 20 countries, with topline results …
This article details the shareholder structure of Lexicon Pharmaceuticals Inc (LXRX), including major individual shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional activity over recent quarters, and key changes in shareholder positions. The report also lists related ETFs that hold …
This article provides an overview of Lexicon Pharmaceuticals Inc (LXRX) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page also presents current stock data including market cap and …
Search by ticker symbol or company name and select a result to open its chart.